U.S. – Talk Bio

Recent Developments in Medical Affairs Reputation and Hemophilia A Management in the US (2025)

2 weeks ago talkbio0Tagged Acquired (qualifier value), Centers for Disease Control and Prevention (U.S.), federal funding, gene therapy, Health Policy, Hemophilia A, Hemophilia A Pipeline, Hemophilia Treatment Centers, HRSA, Medical Affairs, Programs - Publication Format, public health policy, reputation, U.S.

Medical Affairs; Reputation; Hemophilia A; US; 2025; Gene Therapy; Public Health Policies; Hemophilia Treatment Centers; 340B Program; Federal Funding; Acquired Hemophilia A Pipeline; Healthcare Policy; CDC; HRSA

AstraZeneca Onshores Rare Disease Portfolio as Part of $50B US Investment Pledge

3 weeks ago talkbio0Tagged AstraZeneca, expansion, Infrequent, Investments, Maryland (geographic location), onshoring, pledge, portfolio, R&D, U.S., Virginia facility

AstraZeneca; rare disease portfolio; onshoring; US investment; biomanufacturing; $50 billion pledge; Virginia facility; Maryland investment; R&D expansion

US-Backed Group Reports Success with New Tuberculosis Treatment in Phase 2 Study

3 weeks ago talkbio0Tagged Clinical Trials, drug-resistant TB, linezolid, Phase 2 clinical trial, pretomanid, sorfequiline, SPaL, TB Alliance, Treatment Protocols, Tuberculosis, U.S., ultra-short regimen

tuberculosis; TB Alliance; Phase 2 clinical trial; sorfequiline; SPaL regimen; pretomanid; linezolid; drug-resistant TB; ultra-short regimen; US support; clinical trial results

Pharma Investment Surge in US Manufacturing Creates Major Opportunities for CDMOs

1 month ago talkbio0Tagged Advanced therapies, alpha 1-antitrypsin, Biological Factors, capital investment, CDMOs, eli lilly, Growth, Johnson & Johnson, Market, pharmaceutical manufacturing, production, supply chain, U.S.

US pharmaceutical manufacturing; CDMOs; capital investment; Johnson & Johnson; Eli Lilly; biologics; API production; supply chain; advanced therapies; market growth

Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact

2 months ago talkbio0Tagged Clearmind Medicine, Clinical Trials, governmental engagement, Mary-Elizabeth, mental health, partnerships, psychedelic medicine, regulatory advocacy, U.S.

Clearmind Medicine; Mary-Elizabeth Gifford; Chief of Global Impact; psychedelic medicine; US partnerships; governmental engagement; regulatory advocacy; biotech company; clinical trials; mental health

Drugmakers Push US Expansion After Trump’s 100% Pharma Tariff Threat

2 months ago talkbio0Tagged branded drugs, drugmakers, genentech, Manufacturing, Roche (company), Section 232, supply chain, Trump tariff, U.S.

Trump tariff; pharmaceuticals; US manufacturing; branded drugs; drugmakers; Genentech; Roche; Novo Nordisk; Section 232; supply chain

Roche in Talks With US on Drug Pricing; Sets Out Pipeline and Dealmaking Ambitions

2 months ago talkbio0Tagged Benefit, dealmaking, direct-to-consumer sales, drug price, gene therapy, Government, Hemlibra, Investments, manager, Manufacturing, Ocrevus, Pharmaceutical Services, pipeline, R&D, Roche (company), U.S., Vabysmo

Roche; drug pricing; US government; pharmacy benefit managers; direct-to-consumer sales; pipeline; dealmaking; US investment; manufacturing; gene therapy; R&D; Ocrevus; Hemlibra; Vabysmo

Biopharma Deal Activity Shows Uptick in Q3 2025: Signs of Recovery and Emerging Trends

2 months ago talkbio0Tagged assets, Biopharma, China, Early-stage, Europe, Licensing, M&A, Merus, Metsera, Physical activity, Q3, therapeutic diversification, U.S., Verona Pharma

biopharma; Q3 2025; deal activity; M&A; licensing; therapeutic diversification; early-stage assets; China; US; Europe; Metsera; Verona Pharma; Merus; high-value deals